Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach

Off-target binding connotes the binding of a small molecule of therapeutic significance to a protein target in addition to the primary target for which it was proposed. Progressively such off-targeting is emerging to be regular practice to reveal side effects. Chymase is an enzyme of hydrolase class...

Full description

Bibliographic Details
Main Authors: Arooj, Mahreen, Sakkiah, S., Cao, G., Kim, S., Arulalapperumal, V., Lee, K.
Format: Journal Article
Published: John Wiley & Sons, Inc. 2015
Online Access:http://hdl.handle.net/20.500.11937/50090
_version_ 1848758391093067776
author Arooj, Mahreen
Sakkiah, S.
Cao, G.
Kim, S.
Arulalapperumal, V.
Lee, K.
author_facet Arooj, Mahreen
Sakkiah, S.
Cao, G.
Kim, S.
Arulalapperumal, V.
Lee, K.
author_sort Arooj, Mahreen
building Curtin Institutional Repository
collection Online Access
description Off-target binding connotes the binding of a small molecule of therapeutic significance to a protein target in addition to the primary target for which it was proposed. Progressively such off-targeting is emerging to be regular practice to reveal side effects. Chymase is an enzyme of hydrolase class that catalyzes hydrolysis of peptide bonds. A link between heart failure and chymase is ascribed, and a chymase inhibitor is in clinical phase II for treatment of heart failure. However, the underlying mechanisms of the off-target effects of human chymase inhibitors are still unclear. Here, we develop a robust computational strategy that is applicable to any enzyme system and that allows the prediction of drug effects on biological processes. Putative off-targets for chymase inhibitors were identified through various structural and functional similarity analyses along with molecular docking studies. Finally, literature survey was performed to incorporate these off-targets into biological pathways and to establish links between pathways and particular adverse effects. Off-targets of chymase inhibitors are linked to various biological pathways such as classical and lectin pathways of complement system, intrinsic and extrinsic pathways of coagulation cascade, and fibrinolytic system. Tissue kallikreins, granzyme M, neutrophil elastase, and mesotrypsin are also identified as off-targets. These off-targets and their associated pathways are elucidated for the effects of inflammation, cancer, hemorrhage, thrombosis, and central nervous system diseases (Alzheimer's disease). Prospectively, our approach is helpful not only to better understand the mechanisms of chymase inhibitors but also for drug repurposing exercises to find novel uses for these inhibitors.
first_indexed 2025-11-14T09:43:14Z
format Journal Article
id curtin-20.500.11937-50090
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:43:14Z
publishDate 2015
publisher John Wiley & Sons, Inc.
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-500902017-12-05T03:45:44Z Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach Arooj, Mahreen Sakkiah, S. Cao, G. Kim, S. Arulalapperumal, V. Lee, K. Off-target binding connotes the binding of a small molecule of therapeutic significance to a protein target in addition to the primary target for which it was proposed. Progressively such off-targeting is emerging to be regular practice to reveal side effects. Chymase is an enzyme of hydrolase class that catalyzes hydrolysis of peptide bonds. A link between heart failure and chymase is ascribed, and a chymase inhibitor is in clinical phase II for treatment of heart failure. However, the underlying mechanisms of the off-target effects of human chymase inhibitors are still unclear. Here, we develop a robust computational strategy that is applicable to any enzyme system and that allows the prediction of drug effects on biological processes. Putative off-targets for chymase inhibitors were identified through various structural and functional similarity analyses along with molecular docking studies. Finally, literature survey was performed to incorporate these off-targets into biological pathways and to establish links between pathways and particular adverse effects. Off-targets of chymase inhibitors are linked to various biological pathways such as classical and lectin pathways of complement system, intrinsic and extrinsic pathways of coagulation cascade, and fibrinolytic system. Tissue kallikreins, granzyme M, neutrophil elastase, and mesotrypsin are also identified as off-targets. These off-targets and their associated pathways are elucidated for the effects of inflammation, cancer, hemorrhage, thrombosis, and central nervous system diseases (Alzheimer's disease). Prospectively, our approach is helpful not only to better understand the mechanisms of chymase inhibitors but also for drug repurposing exercises to find novel uses for these inhibitors. 2015 Journal Article http://hdl.handle.net/20.500.11937/50090 10.1002/prot.24677 John Wiley & Sons, Inc. restricted
spellingShingle Arooj, Mahreen
Sakkiah, S.
Cao, G.
Kim, S.
Arulalapperumal, V.
Lee, K.
Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach
title Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach
title_full Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach
title_fullStr Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach
title_full_unstemmed Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach
title_short Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach
title_sort finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach
url http://hdl.handle.net/20.500.11937/50090